Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TRAF3

Gene summary for TRAF3

Gene summary.

Gene information	Species	Human
	Gene symbol	TRAF3
	Gene ID	7187
	Gene name	TNF receptor associated factor 3
	Gene Alias	CAP-1
	Cytomap	14q32.32
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	Q13114

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7187	TRAF3	CCI_1	Human	Cervix	CC	5.87e-10	8.68e-01	0.528
7187	TRAF3	CCI_3	Human	Cervix	CC	8.19e-07	6.75e-01	0.516
7187	TRAF3	LZE7T	Human	Esophagus	ESCC	2.33e-03	2.19e-01	0.0667
7187	TRAF3	P2T-E	Human	Esophagus	ESCC	3.22e-22	3.82e-01	0.1177
7187	TRAF3	P4T-E	Human	Esophagus	ESCC	1.64e-11	2.45e-01	0.1323
7187	TRAF3	P5T-E	Human	Esophagus	ESCC	8.07e-11	1.30e-01	0.1327
7187	TRAF3	P8T-E	Human	Esophagus	ESCC	2.25e-08	1.02e-01	0.0889
7187	TRAF3	P9T-E	Human	Esophagus	ESCC	3.00e-05	1.18e-01	0.1131
7187	TRAF3	P10T-E	Human	Esophagus	ESCC	1.55e-03	1.39e-01	0.116
7187	TRAF3	P11T-E	Human	Esophagus	ESCC	1.50e-04	1.43e-01	0.1426
7187	TRAF3	P12T-E	Human	Esophagus	ESCC	8.48e-12	1.65e-01	0.1122
7187	TRAF3	P15T-E	Human	Esophagus	ESCC	3.10e-06	1.44e-01	0.1149
7187	TRAF3	P16T-E	Human	Esophagus	ESCC	4.63e-09	1.90e-01	0.1153
7187	TRAF3	P21T-E	Human	Esophagus	ESCC	1.03e-10	1.50e-01	0.1617
7187	TRAF3	P22T-E	Human	Esophagus	ESCC	2.09e-08	9.27e-02	0.1236
7187	TRAF3	P23T-E	Human	Esophagus	ESCC	1.35e-06	1.78e-01	0.108
7187	TRAF3	P24T-E	Human	Esophagus	ESCC	1.50e-08	1.37e-01	0.1287
7187	TRAF3	P26T-E	Human	Esophagus	ESCC	2.68e-21	2.26e-01	0.1276
7187	TRAF3	P27T-E	Human	Esophagus	ESCC	3.01e-10	1.85e-01	0.1055
7187	TRAF3	P28T-E	Human	Esophagus	ESCC	1.98e-15	2.83e-01	0.1149

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00435888	Esophagus	ESCC	skin development	163/8552	263/18723	6.48e-08	1.14e-06	163
GO:003109818	Esophagus	ESCC	stress-activated protein kinase signaling cascade	154/8552	247/18723	8.53e-08	1.44e-06	154
GO:003150314	Esophagus	ESCC	protein-containing complex localization	139/8552	220/18723	1.14e-07	1.85e-06	139
GO:00705078	Esophagus	ESCC	regulation of microtubule cytoskeleton organization	99/8552	148/18723	1.43e-07	2.29e-06	99
GO:0002262111	Esophagus	ESCC	myeloid cell homeostasis	104/8552	157/18723	1.49e-07	2.36e-06	104
GO:003001018	Esophagus	ESCC	establishment of cell polarity	96/8552	143/18723	1.69e-07	2.67e-06	96
GO:007053413	Esophagus	ESCC	protein K63-linked ubiquitination	44/8552	56/18723	4.84e-07	6.50e-06	44
GO:00510908	Esophagus	ESCC	regulation of DNA-binding transcription factor activity	252/8552	440/18723	5.22e-07	6.97e-06	252
GO:005140318	Esophagus	ESCC	stress-activated MAPK cascade	147/8552	239/18723	5.43e-07	7.18e-06	147
GO:0048872111	Esophagus	ESCC	homeostasis of number of cells	163/8552	272/18723	1.40e-06	1.69e-05	163
GO:00028318	Esophagus	ESCC	regulation of response to biotic stimulus	191/8552	327/18723	2.12e-06	2.45e-05	191
GO:003320914	Esophagus	ESCC	tumor necrosis factor-mediated signaling pathway	67/8552	99/18723	7.87e-06	7.72e-05	67
GO:000283212	Esophagus	ESCC	negative regulation of response to biotic stimulus	72/8552	108/18723	8.36e-06	8.11e-05	72
GO:007030217	Esophagus	ESCC	regulation of stress-activated protein kinase signaling cascade	119/8552	195/18723	1.07e-05	1.01e-04	119
GO:003461220	Esophagus	ESCC	response to tumor necrosis factor	149/8552	253/18723	1.47e-05	1.33e-04	149
GO:1903312111	Esophagus	ESCC	negative regulation of mRNA metabolic process	62/8552	92/18723	2.08e-05	1.80e-04	62
GO:00017387	Esophagus	ESCC	morphogenesis of a polarized epithelium	63/8552	94/18723	2.34e-05	2.00e-04	63
GO:00991114	Esophagus	ESCC	microtubule-based transport	115/8552	190/18723	2.54e-05	2.15e-04	115
GO:003287217	Esophagus	ESCC	regulation of stress-activated MAPK cascade	116/8552	192/18723	2.63e-05	2.21e-04	116
GO:00072549	Esophagus	ESCC	JNK cascade	102/8552	167/18723	4.22e-05	3.39e-04	102

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0517120	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa0541720	Cervix	CC	Lipid and atherosclerosis	65/1267	215/8465	6.47e-09	1.10e-07	6.52e-08	65
hsa0516720	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa0516920	Cervix	CC	Epstein-Barr virus infection	57/1267	202/8465	7.30e-07	7.39e-06	4.37e-06	57
hsa0465718	Cervix	CC	IL-17 signaling pathway	31/1267	94/8465	8.71e-06	7.43e-05	4.39e-05	31
hsa052226	Cervix	CC	Small cell lung cancer	29/1267	92/8465	4.38e-05	3.09e-04	1.83e-04	29
hsa051657	Cervix	CC	Human papillomavirus infection	74/1267	331/8465	1.70e-04	1.02e-03	6.03e-04	74
hsa0516414	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa046686	Cervix	CC	TNF signaling pathway	28/1267	114/8465	4.60e-03	1.62e-02	9.59e-03	28
hsa046213	Cervix	CC	NOD-like receptor signaling pathway	41/1267	186/8465	5.90e-03	1.95e-02	1.15e-02	41
hsa05171110	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa05417110	Cervix	CC	Lipid and atherosclerosis	65/1267	215/8465	6.47e-09	1.10e-07	6.52e-08	65
hsa05167110	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa05169110	Cervix	CC	Epstein-Barr virus infection	57/1267	202/8465	7.30e-07	7.39e-06	4.37e-06	57
hsa0465719	Cervix	CC	IL-17 signaling pathway	31/1267	94/8465	8.71e-06	7.43e-05	4.39e-05	31
hsa0522213	Cervix	CC	Small cell lung cancer	29/1267	92/8465	4.38e-05	3.09e-04	1.83e-04	29
hsa0516512	Cervix	CC	Human papillomavirus infection	74/1267	331/8465	1.70e-04	1.02e-03	6.03e-04	74
hsa0516415	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa0466813	Cervix	CC	TNF signaling pathway	28/1267	114/8465	4.60e-03	1.62e-02	9.59e-03	28
hsa0462112	Cervix	CC	NOD-like receptor signaling pathway	41/1267	186/8465	5.90e-03	1.95e-02	1.15e-02	41

Page: 1 2 3 4 5 6 7 8 9 10 11

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TRAF3

SNV

Missense_Mutation

novel

c.1552A>G

p.Ser518Gly

p.S518G

Q13114

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AN-A0FK-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

TRAF3

SNV

Missense_Mutation

novel

c.1591N>A

p.Ala531Thr

p.A531T

Q13114

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AR-A24T-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cytoxan

TRAF3

SNV

Missense_Mutation

c.599N>C

p.Val200Ala

p.V200A

Q13114

protein_coding

tolerated(0.6)

benign(0.079)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRAF3

SNV

Missense_Mutation

novel

c.1624N>T

p.Val542Phe

p.V542F

Q13114

protein_coding

deleterious(0)

probably_damaging(0.966)

TCGA-E9-A54X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRAF3

insertion

Frame_Shift_Ins

novel

c.1553_1554insATTCTGCACTGTC

p.Ser518ArgfsTer37

p.S518Rfs*37

Q13114

protein_coding

TCGA-AN-A0FK-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

TRAF3

insertion

Nonsense_Mutation

novel

c.194_195insTATTTGATCATGTTTTGTTCCCAACACATATTAAAGTTGG

p.Gln65HisfsTer3

p.Q65Hfs*3

Q13114

protein_coding

TCGA-AR-A0TY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

TRAF3

insertion

Nonsense_Mutation

novel

c.1541_1542insTGGGCCCCGGGCGAGTGCTGGGGCGGGGTCCGTGGGATGAGGG

p.Asp515GlyfsTer13

p.D515Gfs*13

Q13114

protein_coding

TCGA-AR-A0TY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

TRAF3

deletion

Frame_Shift_Del

c.1520_1523delNNNN

p.His507ArgfsTer21

p.H507Rfs*21

Q13114

protein_coding

TCGA-AR-A1AI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

TRAF3

SNV

Missense_Mutation

c.26N>T

p.Ser9Phe

p.S9F

Q13114

protein_coding

deleterious_low_confidence(0.02)

benign(0.037)

TCGA-C5-A1MK-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

carboplatin

TRAF3

SNV

Missense_Mutation

novel

c.1234G>A

p.Ala412Thr

p.A412T

Q13114

protein_coding

tolerated(0.06)

benign(0.183)

TCGA-C5-A7X5-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

carboplatin

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1